|
|
||||||||
Articles |
1
Specialty Laboratories, Inc., Santa Monica, CA 90404-3900.
2
Axis Biochemicals, AS, Oslo, Norway.
a Author for correspondence. Fax 310-828-5173.
| Abstract |
|---|
|
|
|---|
Key Words: indexing terms: carbohydrate-deficient transferrin alcohol abuse diagnosis
| Introduction |
|---|
|
|
|---|
The only CDT procedure commercially available in the US is the Specialty Laboratories (Santa Monica, CA) isoelectric focusing/immunoblotting/laser densitometry (IEF/IB/LD) method, introduced during the early 1990s (9). This and Pharmacia's CDTect, used widely in Europe but available in the US for research purposes only, are pioneer CDT tests used extensively in several clinical settings (1)(3)(4)(5)(6)(7)(8). Both procedures use a charge-based method to separate CDT molecules containing two, one, or no sialic acids, followed by detection in different immunoassays; IEF/IB/LD measures CDT as a ratio of total transferrin, whereas CDTect measures absolute values of CDT.
We describe two new laboratory procedures for evaluation of CDT, Axis (Oslo, Norway) %CDT turbidimetric immunoassay (TIA) and Axis %CDT-HPLC, and compare their performance to that of the pioneer IEF/IB/LD. In addition to measuring (all or a fraction of) the disialo-, monosialo-, and asialotransferrins, both these new procedures include half the concentration of trisialotransferrin in their CDT quantitation schemes and report CDT results as a relative amount to total serum transferrin. The relevance of these new evaluation methods is discussed in the context of their implications for the widespread use of CDT because inclusion of the trisialotransferrin fraction increases the accuracy in the diagnosis of sustained alcohol usage. The Axis %CDT TIA is available in a manual format as well as several semiautomated, cost-effective formats.
| Materials and Methods |
|---|
|
|
|---|
After CDT quantitation by %CDT TIA and %CDT HPLC, all 58 specimens obtained from Axis were shipped frozen as blind samples to Specialty for analysis by IEF/IB/LD. After CDT quantitation by Specialty's IEF/IB/LD, all 20 specimens derived from African Americans were shipped frozen as blind samples to Axis for analysis by %CDT TIA and %CDT HPLC. Serum aliquots were stored for <3 months at -20 °C before analysis; only 76 of the 78 specimens were available for analysis by HPLC.
All patients and controls voluntarily joined the investigation, which complies with the Helsinki Declaration of 1975.
ief/ib/ld procedure
Each serum sample was partially saturated with iron and analyzed
in acrylamide gels containing a gradient of ampholytes as previously
described (9). The carbohydrate composition and iron
content of the two CDT diagnostic bands quantitated in our system,
described in detail elsewhere, represent disialo- and asialotransferrin
isoforms (9)(10). Gels were electrotransferred
onto nylon membranes and incubated with rabbit anti-human transferrin
antibodies, followed by incubation with an alkaline
phosphataseanti-IgG conjugate. The absorbances of the bands separated
by IEF-IB were determined by laser scan densitometry. CDT
quantification, expressed as a ratio of CDT to fully sialylated
transferrin, was determined by measuring the ratio of the absorbances
of the CDT bands vs those of the fully sialylated transferrin bands.
This absorbance ratio (calculated for each specimen) was then divided
by the absorbance ratio obtained for the strong-positive control in
each gel, which served also as a calibrator, multiplied by 100, and
expressed in densitometry units (DU). CDT values represent the mean of
duplicates. Three controls were run in each gel: a nondrinker woman
(CDT-) and two male alcohol abusers: a weak CDT+ and a strong CDT+.
Intra- and interassay variations for the weak CDT+ control are 11% and
16%, respectively.
The cutoff limit was established by an analysis of 100 control individuals (50 women and 50 men) with a reported alcohol consumption of <40 g/week; the mean value plus 2 SD was 7.3 DU for women and men combined (10). Thus, the cutoff was set at 7 DU, and CDT values between 7 and 10 DU, i.e., 2 SD and 3 SD from the mean of the control group, constitute the indeterminate range. When IEF/IB/LD is used in the clinical laboratory, repeat testing is recommended for all those serum specimens with CDT values within this latter range.
%cdt tia
The Axis %CDT TIA is a multistep procedure based on microcolumn
separation followed by a TIA. Serum transferrin is saturated with iron
by mixing 100 µL of serum with 500 µL of an aqueous solution
containing 10 mmol/L Bis-Tris
[bis(2-hydroxyethyl)amino-tris(hydroxymethyl) methane], 0.8 mmol/L
Tris, 0.15 mmol/L FeCl3, 0.15 mmol/L sodium citrate,
0.4 mmol/L maleic acid, 0.5 mL/L Tween 20, and 3.1 mmol/L sodium azide
(Solution 1), pH 7.0. We measured the CDT concentration in 500 µL of
this master mixture, and we determined the concentration of serum
transferrin with 50 µL.
CDT concentration was measured by passing 500 µL of master mixture through a column of 7 mm (i.d.) containing 0.5 mL of Poros HQ10 (Perseptive Biosystems, Framingham, MA). Thereafter, 1.0 mL of Solution 2 (elution buffer), adjusted to pH 6.0 with 1 mol/L HCl and 5 mmol/L NaCl, was added, and the eluate was discarded. Another 2 mL of Solution 2 was added, and the eluate was collected to determine the concentration of CDT (asialo-, monosialo-, disialo-, and 50% of the trisialotransferrins) eluted from the column. In minicolumns, a complete baseline separation between the isotransferrins is difficult to obtain. Including all trisialotransferrins would cause a contamination of tetrasialotransferrins that should be avoided in the eluate. The 50% trisialotransferrin value, calculated through calibration by %CDT HPLC, is therefore a compromise between the clinically ideal 100% trisialotransferrin fraction and avoidance of tetrasialotransferrins in the eluate.
To each well of a microtiter plate was added 200 µL of the eluates from the minicolumn, and the absorbance was determined spectrophotometrically at 405 nm in a microtiter plate reader. A polyclonal anti-human transferrin antibody solution (100 µL; 1 g/L) and 60 g/L polyethylene glycol in 300 mmol/L Tris, pH 7.4, were added to each well, and the absorbance was determined again after 15 min. To obtain a concentration of eluted CDT, the difference in absorbances is interpolated in a calibration curve obtained with transferrin calibrators of 2, 10, 16, and 32 mg/L.
The concentration of serum transferrin was determined by diluting 50 µL of master mixture with 2 mL of Solution 2, and the absorbance was measured at 405 nm as specified for CDT, before and after addition of the polyclonal anti-transferrin antibody. After the difference in absorbances in the same calibration curve was interpolated, the %CDT:transferrin ratio was calculated for each serum sample in single determinations; the upper reference limit value was 6% for both women and men. Intra- and interassay variations are 4% and 5%, respectively. The reference range was established by CDT evaluations in 43 total abstainers, members of a Norwegian anti-drinking organization, ages 30 to 82 years, and 108 social drinkers, healthy individuals of both sexes, ages 18 to 70 years, consuming an average of <40 g of alcohol daily according to an interview at the time of blood sampling. All total abstainers showed CDT values <5%, whereas 4 of 108 social drinkers showed CDT values >6%. Thus, the upper reference limit was defined as 5% and 6% for total abstainers and social drinkers, respectively.
hplc analysis
Analytical HPLC separation was performed at room temperature in a
standard HPLC system (Pharmacia Biotech, Uppsala, Sweden) by a
procedure similar to the one described by Jeppsson et al.
(11). A Pharmacia HR 5/5 column is high-flow-packed (79
mL/min) with Porus HQ10 particles (Perseptive Biosystems) to a gel
height of 60 mm. Serum specimens (150 µL) were mixed with the same
Fe(III)-Tris-maleic-citrate solution (Solution 1, 30 µL, pH 7) as
described for the %CDT TIA, and the samples were incubated for 30 min
at room temperature. After incubation, 1.6 µL of dextran sulfate (100
g/L in water) and 7.5 µL of CaCl2 (147 g/L in water) were
added to precipitate lipoproteins. The samples were refrigerated for
1 h at 46 °C before removal of the precipitated lipoproteins
by centrifugation (5000g) for 15 min at 46 °C. The
clear supernates (130 µL) were poured off and diluted 19.5-fold with
water and, after a 10-min delay, filtered with a syringe filter (0.22
µm pore size) before injection onto the chromatographic column.
Sample storage at 46 °C overnight before HPLC analysis causes no
detectable alteration of CDT content.
The isoforms of transferrin were separated in a two-buffer system with a multistep salt gradient elution at a flow rate of 2.0 mL/min. Mobile phase A is 20 mmol/L Bis-Tris buffer (Fluka Biochemica, Buchs, Switzerland), pH 6.20. Mobile phase B is 20 mmol/L Bis-Tris buffer, pH 5.60, containing 17.5 g of NaCl per liter (300 mmol/L). Regeneration/cleaning solution consists of equal volumes of methanol and 1 mol/L HCl. Injection of 2 mL of sample volume was optimal with respect to eluant dilution, resolution, and signal intensity.
Peak evaluations in the chromatogram were performed with a Nelson data module. The total transferrin concentration is calculated by baseline integration of all transferrin isoforms; the %CDT concentration is expressed as a relative amount (%) to total transferrin by peak integration calculated for the mono-, di-, and 50% of the trisialotransferrins. Intra- and interassay variation is <5%. The ionic strength of the buffer used in the minicolumn assay was calibrated until the correlation between the HPLC and TIA methods was at maximum. The upper reference limit of 6% CDT was defined as described for the %CDT TIA.
statistical analysis
The intraassay variation was calculated by assaying the 3 control
specimens, CDT-negative, CDT weak-positive, and CDT strong-positive
sera, 15 times each in the same run. The interassay variation was
calculated by assaying the same 3 control sera 15 times each in
different runs.
We compared the results of the three assays according to the nonparametric Spearman's correlation coefficient. Diagnostic test performance was evaluated by ROC curve analysis (12), and the area under the ROC curve was calculated by the method of Hanley and McNeil (13) with True EpistatTM software (Epistat Services, Richardson, TX).
| Results |
|---|
|
|
|---|
|
correlation between the cdt tests
The correlation between IEF/IB/LD and %CDT TIA
(r = 0.71, P <0.0001) (Fig. 2
, left) was similar to the correlation between IEF/IB/LD and %
CDT HPLC (r = 0.78, P <0.0001)
(Fig. 2
, middle). This similarity was expected because all three tests
measure relative CDT concentrations rather than absolute CDT values
circulating in the blood. The correlation between %CD TIA and %CDT
HPLC (r = 0.88, P <0.0001) (Fig. 2
, right) was the highest among all three procedures because HPLC is not
only the confirmatory method but also the calibrator for the
turbidimetric immunoassay. In serum samples from two alcohol abusers
ingesting >100 g/day, %CDT TIA and %CDT HPLC rendered values
slightly above the cutoff (6% CDT), whereas IEF/IB/LD rendered a
false-negative CDT result. Another alcohol abuser was CDT-positive by
IEF/IB/LD only. Serum specimens derived from three social drinkers
tested CDT-positive by IEF/IB/LD, one of whom was also CDT-positive by
%CDT TIA but CDT-negative by HPLC. Two African American social
drinkers who are carriers of transferrin genetic D variants and three
alcohol abusers tested CDT-negative in all three tests.
|
specificity and sensitivity
The individual CDT values in patients and apparently healthy
controls is shown in dot plots (Fig. 3
). The results of the Axis %CDT TIA show CDT values below the
cutoff (6%) for 8 of 8 total abstainers, 7 of 7 pregnant women and 32
of 33 social drinkers, whereas CDT-positive results were obtained for
26 of 30 alcohol abusers (Fig. 3
, top). The sensitivity and specificity
within this population were 87% (26 of 30) and 98% (47 of 48),
respectively.
|
The results of the IEF/IB/LD in this same population are CDT-negative
results (<7 DU) in 8 of 8 total abstainers, 7 of 7 pregnant women, and
30 of 33 social drinkers, whereas CDT-positive results were obtained in
25 of 30 alcohol abusers (Fig. 3
, middle). The sensitivity and
specificity within this population were 83% (25 of 30) and 94% (45 of
48), respectively.
%CDT HPLC resulted in CDT values below the cutoff established at 6%
for 7 of 7 total abstainers, 7 of 7 pregnant women, and 32 of 32 social
drinkers, whereas CDT-positive values were found in 26 of 30 alcohol
abusers (Fig. 3
, bottom). At a specificity of 100% (46 of 46), the
sensitivity of %CDT-HPLC was 87% (26 of 30). The resemblance of the
data between both Axis procedures reflects their high correlation
coefficient.
roc analysis: test comparison
The diagnostic efficacy of IEF/IB/LD, %CDT TIA, and % CDT HPLC,
defined as the ability to obtain a CDT-positive result when heavy
alcohol consumption truly exists (sensitivity or true-positive rate)
and to give CDT-negative results when heavy alcohol consumption does
not occur (specificity or true-negative rate), are compared in ROC
curves (Fig. 4
). ROC analysis is a statistical tool that shows sensitivities
and specificities for all possible cutoffs in these three tests. At
100% specificity (0% false-positive rate), the sensitivity of both
Axis procedures is >87%, whereas the sensitivity of IEF/IB/LD is
<50%. This improved clinical utility is shown by a ROC curve that
forms an approximate right angle at the upper left side of the ROC
plot. The areas under the ROC curves are 0.89, 0.93, and 0.96 for
IEF/IB/LD, %CDT HPLC, and %CDT TIA, respectively.
|
predictive values
The diagnostic accuracy for all three CDT procedures was analyzed
by means of their predictive values, assuming a prevalence of 7% of
alcohol abuse in the US population (14). The
identification of true alcohol abusers among all CDT-positive
individuals [positive predictive value (PPV)] as well as predictions
for bona fide nondrinkers among all CDT-negative individuals [negative
predictive value (NPV)] was calculated with the cutoff values
established for each test (Table 1
). All three CDT procedures show the same optimal NPV (0.98);
i.e., 98% of individuals with a CDT-negative result are nondrinkers.
The PPV varied from 0.5 for the IEF/IB/LD to 0.75 for the %CDT TIA and
1.0 for the %CDT HPLC. Therefore, only one-half (50%) of individuals
with positive CDT results by IEF/IB/LD correspond to true alcohol
abusers, and one-half (50%) represent false-positives compared with
%CDT TIA and %CDT HPLC with 75% and 100% accuracy rates,
respectively.
|
| Discussion |
|---|
|
|
|---|
The pioneer IEF/IB/LD was the first CDT procedure to measure CDT as a ratio of total serum transferrin; CDTect measures absolute values of circulating CDT. CDT:transferrin ratios provide increased diagnostic accuracy rather than absolute CDT values because individuals with high or low serum transferrin concentrations will render a false-positive or a false-negative result, respectively, with CDTect. Like IEF/IB/LD, %CDT TIA and %CDT HPLC measure CDT as fractions of total serum transferrin.
An ROC curve is the best way to compare the diagnostic performance of different procedures because it shows sensitivities and specificities for all possible cutoffs in a test. In this study, the dot plots illustrate the distribution of individual values obtained by each procedure, whereas the ROC plot compares the diagnostic performance of the three CDT tests. Both Axis procedures perform better diagnostically than the IEF/IB/LD, which measures asialo- and disialotransferrin, but not the trisialotransferrin isoforms. A similar ROC curve was obtained for the IEF/IB/LD procedure as for the CDTect, a finding that supports the reliability of the former as a comparison method for the validation of new CDT tests (4).
Clinical outcome decides whether the test results would assist in improving the patient's health at an affordable cost and includes the efficacy variables of the test: sensitivity, specificity, PPV, and NPV (15)(16).
Sensitivity answers the question: "If the patient has the disease, how likely is he to have a positive test?" Specificity answers the question: "If the patient does not have the disease, how likely is he to have a negative test?" A clinician's question is, "If the patient has a positive test, how likely is he to have the disease?" or "If the patient has a negative test, how likely is he not to have the disease?" (17).
In family practice, most conditions, including alcohol abuse, are of low prevalence. The PPV will be lower and the NPV will be higher in populations with low prevalence for a disorder (18). Because the prevalence of alcohol abuse is 57% in the US, positive CDT results are more likely to represent false positives than true positives. CDT procedures like IEF/IB/LD show a PPV of 50% in the general population; i.e., only one of two CDT-positive results reflect identification of a true alcohol abuser. The clinical utility of this pioneer CDT procedure in detecting alcohol abuse in the general population would be much improved if the assay was used as a reflex test after screening with more-conventional diagnostic tests (19). Thus, with the same sensitivity and specificity rates described for the IEF/IB/LD, the PPV increases from 0.5 to 0.8 in a preselected population where the prevalence of alcohol abuse is 25%.
Previous results have been discouraging for CDT used to screen the general population (6)(7)(8)(20). The Svalbard study defined heavy drinkers according to the amount of alcohol ingested by the 95th percentile of the population examined, e.g., 52 g/day for men (6). However, the optimal diagnostic performance of CDT has been reported for an alcohol consumption of at least 60 g/day for 710 consecutive days (1)(2)(3)(4)(5). The Copenhagen study used a cutoff point for CDT that maximized sensitivity (82%) rather than specificity (77%) (21). Considering the low prevalence of alcohol abuse in the general population, at a specificity of 77% the PPV is <0.2. Bell et al. (8) reported a sensitivity of 69% at 92% specificity for 502 patients admitted consecutively to a medical department, a value similar to that generally described for CDTect in individuals ingesting >50 g of alcohol per day.
Newly emerging procedures like %CDT TIA and %CDT HPLC, however, provide increased diagnostic performance because of improved sensitivity and specificity (22). Thus, the PPV improved from 0.5 for IEF/IB/LD to 0.75 with these new, semiautomated CDT tests; three of four alcohol abusers like the ones defined in this study (group 4) could now be accurately identified in a clinical practice. CDT procedures like %CDT TIA and %CDT HPLC show the benefits of improved diagnostic performance and cost-effective automation, with the potential for widespread use of this marker in several clinical settings. Whether the inclusion of the trisialotransferrins results in improved efficacy of the test awaits further analysis of the carbohydrate composition of CDT.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
how useful are they in population studies: The Svalbard Study 198889. Alcohol Clin Exp Res 1992;16:82-86.
[ISI][Medline]
[Order article via Infotrieve]
The following articles in journals at HighWire Press have cited this article:
![]() |
P. Anttila, K. Jarvi, J. Latvala, and O. Niemela METHOD-DEPENDENT CHARACTERISTICS OF CARBOHYDRATE-DEFICIENT TRANSFERRIN MEASUREMENTS IN THE FOLLOW-UP OF ALCOHOLICS Alcohol Alcohol., January 1, 2004; 39(1): 59 - 63. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Anttila, K. Jarvi, J. Latvala, J. E. Blake, and O. Niemela DIAGNOSTIC CHARACTERISTICS OF DIFFERENT CARBOHYDRATE-DEFICIENT TRANSFERRIN METHODS IN THE DETECTION OF PROBLEM DRINKING: EFFECTS OF LIVER DISEASE AND ALCOHOL CONSUMPTION Alcohol Alcohol., September 1, 2003; 38(5): 415 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tagliaro, F. Bortolotti, R. M. Dorizzi, M. Marigo, J. R. Delanghe, B. Wuyts, and M. L. De Buyzere Caveats in Carbohydrate-deficient Transferrin Determination Drs. Delanghe, Wuyts, and De Buyzere respond: Clin. Chem., January 1, 2002; 48(1): 208 - 209. [Full Text] [PDF] |
||||
![]() |
R. F. Anton, C. Dominick, M. Bigelow, and C. Westby Comparison of Bio-Rad %CDT TIA and CDTect as Laboratory Markers of Heavy Alcohol Use and Their Relationships with {gamma}-Glutamyltransferase Clin. Chem., October 1, 2001; 47(10): 1769 - 1775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Helander, M. Fors, and B. Zakrisson STUDY OF AXIS-SHIELD NEW %CDT IMMUNOASSAY FOR QUANTIFICATION OF CARBOHYDRATE-DEFICIENT TRANSFERRIN (CDT) IN SERUM Alcohol Alcohol., September 1, 2001; 36(5): 406 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lacey, H. R. Bergen, M. J. Magera, S. Naylor, and J. F. O'Brien Rapid Determination of Transferrin Isoforms by Immunoaffinity Liquid Chromatography and Electrospray Mass Spectrometry Clin. Chem., March 1, 2001; 47(3): 513 - 518. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Wuyts, J. R. Delanghe, I. Kasvosve, A. Wauters, H. Neels, and J. Janssens Determination of Carbohydrate-deficient Transferrin Using Capillary Zone Electrophoresis Clin. Chem., February 1, 2001; 47(2): 247 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dibbelt Does Trisialo-Transferrin Provide Valuable Information for the Laboratory Diagnosis of Chronically Increased Alcohol Consumption by Determination of Carbohydrate-deficient Transferrin? Clin. Chem., August 1, 2000; 46(8): 1203 - 1205. [Full Text] [PDF] |
||||
![]() |
J. B. Whitfield, L. M. Fletcher, T. L. Murphy, L. W. Powell, J. Halliday, A. C. Heath, and N. G. Martin Smoking, obesity, and hypertension alter the dose–response curve and test sensitivity of carbohydrate-deficient transferrin as a marker of alcohol intake Clin. Chem., December 1, 1998; 44(12): 2480 - 2489. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Viitala, K. Lahdesmaki, and O. Niemela Comparison of the Axis %CDT TIA and the CDTect method as laboratory tests of alcohol abuse Clin. Chem., June 1, 1998; 44(6): 1209 - 1215. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Arndt, R. Hackler, and P. Bean Evaluation of Carbohydrate-deficient Transferrin Dr. Bean responds: Clin. Chem., May 1, 1998; 44(5): 1069 - 1071. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |